19 Sep 2019
Nowadays, everyone is attempting to save, reduce, and cut back – except when regulatory requirements are involved. Such requirements are becoming more comprehensive and more challenging. Especially when it comes to the quality of pharmaceutical products. Over the course of the last 100 years, good manufacturing practice (GMP) has resulted in substantial requirements for drug product safety. But these GMP guidelines didn’t appear out of thin air and they haven’t been developed by the authorities over a short period of time. Rather, they involve all of the experiences – some of which, unfortunately, have involved serious events – over time. The following article is intended to raise awareness of the need to focus once again on GMP and to reach a broad audience across all corporate levels.
Throughout life, people suffer from a variety of ailments that take different courses and have various manifestations. In most cases, people turn either on their own, or on the advice of their doctor, to medication to ease the symptoms and treat their illness. Of course, this raises the question of whether the medication used to treat the illness is effective and whether the person using it will be able to tolerate it. Furthermore, as a result of headlines in the news, we are now highly aware of the issue of drug safety.
Effectiveness, tolerance, and safety are very much determined by the quality of the drug product. Quality, in turn, depends on the production of the active ingredients and accompanying substances that are used, the combination and assembly of these substances, packaging, storage and transportation, the experience and training of all participants, the validation of procedures, the qualification of systems, and the service providers and consultants involved in the process. As a result, there are numerous actors and potential sources of errors that have a direct impact on quality.
These considerations are especially important with respect to vaccines. Because vaccines are produced using biological and genetic engineering processes, steps must be taken to prevent contamination. The processes used to ensure quality of medicines and vaccines must be flawless, nothing left to chance. Patients assume all parties involved - manufacturers, labs, packagers, warehouse workers, transporters, and pharmacists – meet all quality requirements at all times and trust the medicines is safe.
But, is trust enough when it comes to your health? Most probably not. This is where regulations come in. They are precise requirements that must be observed with respect to the production, storage, transportation, testing, and sale of drug products. These are the rules of GMP. As global standards, they are defined in national laws around the world, such as in Germany, they are outlined in the Medicinal Products Act (AMG).
“This article is intended for everyone who is involved in the production, packaging, storage, transportation, or other handling of raw materials and active substances, drug products, and vaccines; it should be made available to all such persons. It is intended to draw attention, make people aware of the issue, and provide a good justification for GMP – in short, it is intended to be a simple and easy-to-understand training tool.” Björn Niggemann
GMP regulations can be scary. Immense documentation requirements, technical knowledge beyond capabilities, fear of fines, and the list of concerns goes on. However, it’s important to understand that GMP touches every department in your organization. The sooner you get everyone onboard, educated and trained, the sooner these concerns turn into everyday business like clockwork.
The women and men who work in the pharmaceutical industry have a wide variety of training levels and specializations: from sales staff to engineers, from lab assistants to cleaning specialists. But, because the regulatory frameworks, laws, guidelines and regulations around the world are so complex; their impact can be felt beyond the production sites and labs. They can also affect all corporate levels.
Therefore, all employees must understand the aim and purpose of their role, their work, and how GMP regulations affect their work. A willingness to assume responsibility in this regard is essential to ensure the health risk to patients – and the associated economic risks to the company – have been minimized as much as possible. Ultimately, a company will realize that there is a break-even point for the effort and the reward of the additional work caused by the GMP; and the net gain will be your company’s compliance.
History shows (see download below) that patients have suffered serious negative health consequences – and in some cases even death – as a result of errors in the production process or as a result of errors during the analysis stage. In many instances, these errors could have been avoided if GMP requirements had applied at the time.
Download a historical recount of drug safety events and regulations as they developed over the years from 1937 – 2018. A fascinating look at the motivators behind drug safety regulations and vital importance of today’s GMPs.
Drug products are developed and produced in order to prevent or cure illnesses or to provide ill patients with relief. Drug products are purchased with the trust and the confidence that the manufacturers do everything they can during the production and development process to ensure high quality and prevent risks during the process . The awareness that drug products can lead to substantial risks arose, in part, in the early 1960s as a result of the Contergan scandal, when deformations and deaths occurred among infants after their mothers had taken sleeping aids while they were pregnant. At nearly the same time, millions of people accidentally became infected with the SV40 simian virus when they were immunized against polio because the oral vaccine was contaminated. SV40 can cause cancer. For example, SV40 viruses cause lymphomas, lung cancer, bone cancer, and brain tumors in hamsters . This shows that the risk potential of a medication that has not been tested sufficiently or that has become contaminated or otherwise tainted or been the subject of an act of sabotage should not be underestimated. To prevent such risks, standards to ensure a uniform quality assurance system (QA system) must be developed on a continuous basis.
However, GMP itself is not a QA system, but instead only provides specific instructions for production processes and for controlling the products that are manufactured. GMP must be integrated in an existing, functional Quality Management System (QMS).
In Germany, compliance with GMP is mandated by law in Section 54 of the AMG. The underlying framework are the EU GMP guidelines, which since 2006 have consisted of two large sections and the related annexes. The actual authorization to manufacture, distribute, or test drug products is provided by the manufacturing authorization pursuant to the AMG; in Germany, such authorization is granted by various authorities, including district governments, regional councils, and other state authorities.
In the US, the Food and Drug Administration (FDA) is the sole agency responsible for food and drug products. Title 21 CFR Part 211 outlines the GMP Requirements for finished pharmaceutical products.
The GMP guidelines, which were originally published by the World Health Organization (WHO) in 1968, have been updated continuously since the 1980s. Based on these guidelines, there is an obligation for both manufacturers and product analysts to define, prior to the introduction of a drug product on the market, a mandatory, multistage approval process. This obligation was first defined in the US . The first US law related to drug products was the Pure Food and Drug Act of 1906, which required that drug products be clearly labeled; however, this law did not introduce an approval process. This occurred three decades later with the Federal Food, Drug, and Cosmetic Act of 1938, which was passed as a result of the sulfanilamide disaster (see table), in which more than 100 people died after taking an antibiotic that had not been tested sufficiently . The key provisions of this law were strengthened by the Kefauver Harris Drug Amendment of 1962, which was passed at the same time as the revelation of the Contergan scandal. This amendment required, for the first time, proof of a drug’s therapeutic effectiveness and safety as shown in adequate and well-controlled clinical studies. A number of drug laws in other countries subsequently also required proof of a drug’s effectiveness. In many respects, US drug laws since 1962 have served as a model used by a large number of other countries .
Internationally, guidelines regarding how and under what conditions drug products may be developed and manufactured have been formulated and enshrined in law in order to ensure and continuously improve product quality. Taken together, all of these guidelines and laws are called GMP. Strict implementation of, compliance with, and adherence to GMP is the most important duty of pharmaceutical companies and testing labs during their day-to-day activities .
In Germany, companies have only been allowed to produce approved drug products if they have demonstrated that they are suitable manufacturers by receiving official authorization since the introduction of the AMG in 1976. On the basis of official inspections, such suitability is carefully reviewed by representatives of the state (inspectors) and, if the manufacturer is deemed to be suitable, documented in a manufacturing authorization in accordance with Section 13 of the AMG. After the initial inspection, the official representatives conduct additional checks at regular intervals (in Germany, every two to three years, using a risk-based approach). The details are set out in the General Administrative Regulations for the Implementation of the AMG (Allgemeine Verwaltungsvorschrift zur Durchführung des Arzneimittelgesetzes – AMGVwV).
What remains is the question of how to go about this. How is GMP to be implemented? Although there are numerous laws, guidelines, and regulations that address the topic of GMP, the level of detail that has been defined with respect to their actual implementation is usually insufficient. As a result, each individual company must generally decide for itself how to ensure a “certified GMP environment”. We will look more closely at this question of how to implement GMP in the next section.
As a result of advances in research, the requirements imposed on the manufacturers of pharmaceutical products are becoming increasingly complex and more time-consuming. At the same time, however, the requirements for management structures from a regulatory perspective are also increasing, as it is now necessary for companies to have at least one quality assurance manager (though they generally must have an entire quality assurance department). This department is responsible for implementing and monitoring tasks within their area of activities related to compliance with quality standards, and its members are appointed directly by management.
The era when the rules of GMP were applied solely to production is over. “Everyone involved in the long value chain of a medication are now affected by GMP and must adhere to the corresponding requirements. In addition to the manufacturer, this also includes retailers, service providers, service technicians, software suppliers, and even garbage disposal companies.” 
The overarching goal of quality assurance (QA) is to establish a QA system within each company that ensures implementation of the applicable national and international rules, ordinances, and laws, including, in particular, GMP. The department must therefore ensure seamless and complete proof of the existence of the necessary QA system .
As indicated above, GMP has changed over the course of the last century. These changes were mainly due to events that can still be found in the media today and that are discussed regularly at GMP conferences, training sessions, and meetings in order to raise awareness of the need for GMP.
The ‘History of GMP’ download accompanying this article summarizes prominent historical events that were important in the history of GMP and also for the development of this standard.
Some studies still show GMP failures on the rise. In the 2018 reporting period, the Federal Union of German Associations of Pharmacists (ABDA) alone produced a total of 9'486 spontaneous reports/notices about drug product risks/side effects from 4'846 pharmacists. Thus, the trend since 2015 has unfortunately been on the rise. Nearly 2'959 reports involved observations of undesired effects or the misuse or improper use of drug products that were forwarded to the competent higher federal authorities. The vast majority of reports received involved complaints about pharmaceutical quality (with 6'527 such cases), with packaging errors leading the way, followed by preparation defects, mechanical problems, and declaration errors. In addition, there were a total of 53 reports of suspected manipulations or counterfeits (2017: 57 reports). The authorities responsible for monitoring the relevant authorization holder were immediately notified in around 40 percent of reports (2'570 of 6'527 reports) relating to suspected quality defects.
The reporting pharmacists also made a significant contribution in 2018 to increasing the safety of drug products and therapies, and thus patient safety. There were a total of 43 DCGMA notices based on 181 reports from 147 pharmacists. Another 660 spontaneous reports from 593 pharmacists led to the initiation of corrective, risk-minimizing measures by the relevant manufacturer. 
The trend is clear: there has (once again) been an increase in defects since 2015. This trend runs counter to GMP and means that the rules must be introduced, applied, and monitored even more forcefully, including in other countries around the world, in order to avoid unnecessarily endangering the health and well-being of patients. Thus, GMP makes absolute sense and must serve as an example and be implemented at all levels.
The events of the last years, and century, are just examples of what can happen during the production, testing, and sale of drug products and the resulting consequences. The list of mishaps could be longer.
But why do they occur in the first place? Among other things, enormous cost pressure is increasingly driving pharmaceutical companies to import cheap starting materials and finished drug products from non-European countries, mainly from Asia. It is difficult to ensure that these manufacturers are complying with domestic quality requirements. In any case, there is no full traceability.
Costs versus quality – this is a difficult balancing act, but one that can be mastered effectively with the help of GMP rules. For example, the Drug Commission of the German Medical Association (DCGMA) published 40 so-called red-hand warnings for 2018 on its website informing manufacturers and associations of manufacturers of finished drug products about potential risks and recalls of drug products . Additional risk warning letters about potential health and other risks can be found on the website of the Federal Institute for Drugs and Medical Devices (BfArM).
The next patient could be you yourself, a member of your family, or your beloved pet! We want to achieve the highest level of safety – this starts with each one of us in our daily work.
However, we now have an increasing number of independent GMP requirements, such as GMP for Advanced Therapy Medicinal Products (ATMP) and GMP for sterile drug products. In addition, there are ever more detailed documents, such as Annex 1 and Annex 17 of the EU GMP guidelines. So let’s rise to the challenge and make medication safe.
The article was first published in the German magazine PM QM 2019, Edition 02/2019.
To take a deeper dive into each GMP Chapter to understand how it relates to quality processes and environmental monitoring, read the next blog article in this series Lessons of GMP: Step by Step Practical Guide Part 2 of 3.
Björn Niggemann has been working for ELPRO-BUCHS AG as Chief Quality Officer since April 2016. In 2004, he was initially commissioned to set up and implement GMP system on existing 17025 accreditation. In 2007he built up a GMP system for an existing GLP system as Compliance Manager. From 2009 to 2010 he worked for a pharmaceutical service provider as GLP / cGMP as Quality Compliance Manager. From 2010 to 2016 Bjoern worked in a Swiss biotech company in the role of Head of Operations and Quality. Today he still heads the working group GDP of GQMA - Germany Quality Management Association e.V. and is thus a member of the extended board. Contact: firstname.lastname@example.org | LinkedIN
 Werani J, Czeromin G, Haas S: compact GMP, GMP-Regeln in der Übersicht. In: PTS Training Service, 2008, 5. Auflage.
 Lehnen-Beyel I: Leukämie durch Affenvirus? In: Bild der Wissenschaft, Konradin Mediengruppe, 2004.
 Peither T, Rempe P, Büßing W: Qualifizierung (Vorabauszug), Maas & Peither AG, 2008.
 Aus wikipedia, URL: https://de.wikipedia.org/wiki/Sulfanilamid-Katastrophe (letzter Aufruf: 10.04.2019).
 Deutsch E, Spickhoff A: Arztrecht, Arzneimittelrecht, Medizinprodukterecht und Transfusionsrecht. In: Medizinrecht, 2003.
 Schnettler R: GMP Basistraining. In: Kursunterlagen PTS Training Service.
 Prinz H: Aufbau, Implementierung und Ausbau eines Qualitätsmanagementsystems in einem pharmazeutischen Unternehmen. In: PharmInd, 1999, Heft 61, Nr. 2.
 Kleist P, Zerobin Kleist C: Eine Kurzgeschichte der klinischen Studie. In: Schweizerische Ärztezeitung, 2005, 86, Nr. 44, Seite 2476.
 Bren L: FDA Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History, URL: https://pdfs.semanticscholar.org/5f81/264165bed665f11ad0f37d6569ce83c98784.pdf?_ga=2.207269331.1781244790.1558526252-1103125071.1558526252 (letzter Aufruf: 22.05.2019).
 Sjöstrom H, Nilsson R: Thalidomide and the Power of the Drug Companies. In: Penguin Books, 1972; deutsche Übersetzung: Contergan oder die Macht der Arzneimittelkonzerne, in VEB Verlag Volk und Gesundheit, Berlin(Ost), 1975.
 US FDA. Milestones in U.S. Food and Drug Law History, https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/milestones-us-food-and-drug-law-history (22.05.2019) (letzter Aufruf: 22.05.2019).
 Wenzel J: Arzneimittelproduktion in den USA. In: Pharm. Ind., 1995, 57, Nr. 2.
 Feuerhelm K: GMP – Was ist das? In: PTS Training Service, 2000.
 Schnettler R: Basistraining Validierung. In: Kursunterlagen PTS Training Service, 2008, Seite 7.
 Peither T, Rempe P, Büßing W: Qualifizierung. In: Maas & Peither AG, 2008, Tab. 1-1.
 Brief an die FDA, Establishment, Maintenance, and Availability of Records Docket No. 02N-0277; RIN 0910-AC39, URL: https://www.federalregister.gov/documents/2014/04/04/2014-07550/establishment-maintenance-and-availability-of-records-amendment-to-record-availability-requirements (letzter Aufruf: 22.05.2019).
 Schnettler R: GMP Basistraining. In: Kursunterlagen PTS Training Service, 2008, Seite 7.
 Schnettler R: Basistraining Validierung. In: Kursunterlagen PTS Training Service, 2008, Seite 8.
 Brendelberger G: Barr Urteil, concept Heidelberg, GMP News, 2005, URL: http://www.gmp-navigator.com/nav_news_554.html (letzter Aufruf: 21.05.2019).
 nks/AFP Norbert Kuls: Schering-Plough zahlt 500 Mio. US Dollar. In: Frankfurter Allgemeinen Zeitung vom 18.05.2002.
 Satista, Florian Diekmann: Rechtsstreit um Vioxx: Merck zahlt fast eine Milliarde Dollar . In: Spiegel Online URL: https://www.spiegel.de/wirtschaft/unternehmen/rechtsstreit-um-vioxx-merck-zahlt-fast-eine-milliarde-dollar-a-799381.html vom 23.11.2011 (zuletzt aufgerufen am 22.05.2019)
 chs/AFP/APChristoph Seidler: Heparin-Skandal – Pharmakonzern spricht von absichtlicher Verunreinigung. In: Spiegel-Online vom 30.04.2008.
 Arne Perras, Süddeutsche Zeitung, Tödliche Medizin, Beitrag vom 17. Mai 2010, URL: https://www.sueddeutsche.de/panorama/schmerzmittel-skandal-in-nigeria-toedliche-medizin-1.486162 (zuletzt aufgerufen am 22.05,2019)
 Adama Ulrich, Deutschlandfunk Kultur, Der Fall Duogynon – ein wenig beachteter Medikamentenskandal, Beitrag vom 04.07.2016, URL: https://www.deutschlandfunkkultur.de/pharma-industrie-der-fall-duogynon-ein-wenig-beachteter.976.de.html?dram:article_id=358848 (zuletzt aufgerufen am 22.05.2019) •
 Reuters, ZEIT ONLINE: Pharma-Skandal:Großrazzia gegen chinesische Medikamentenfälscher, Beitrag vom 05.08.2012, URL: https://www.zeit.de/wissen/gesundheit/2012-08/china-medikamente-faelschung (zuletzt aufgerufen am 22.05.2019)
 Marc Iseli (ise) /Schweizerische Depeschenagentur (sda), in Handelszeitung online, Tausende Missbildungen wegen Sanofi-Medikament, Beitrag erschienen am 21.04.2017, URL: https://www.handelszeitung.ch/unternehmen/tausende-missbildungen-wegen-sanofi-medikament-1387047 (zuletzt aufgerufen am 22.05.2019)
 Seher D: Krebsmittel-Skandal – Gepanschte Medikamente aus der Apotheke. In: Tagesspiegel vom 08.11.2017, URL: www.tagesspiegel.de/gesellschaft/panorama/krebsmittel-skandal-gepanschte-medikamente-aus-der-apotheke/20557446.html (letzter Aufruf: 21.05.2019).
 Website der Arzneimittelkommission der deutschen Ärzteschaft, URL: www.akdae.de/Arzneimittelsicherheit/RHB/index.html (letzter Aufruf: 21.05.2019).
 Webseite der Arzneimittelkommission der Deutschen Apotheker, URL: www.abda.de/themen/arzneimittelsicherheit/amk/zahlen-und-fakten/ (letzter Aufruf: 21.05.2019).